Concepedia

Laure A Moutouh-de Parseval

LA

Statistics

Publications

4

Citations

1.8K

H-Index

4

Active since

2008

Affiliations

Novartis (Switzerland)(Current)

Isala

Centre Hospitalier Universitaire de Bordeaux

Institut Gustave Roussy

University Hospital Heidelberg

Laure A Moutouh-de Parseval is an author at Novartis (Switzerland) specializing in medicine, molecular oncology, and cancer therapeutics.

Top concepts

Publications per year

2008–2018

4

Publications

4

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

Reinhard Dummer, Paolo A. Ascierto, Helen Gogas et al. · The Lancet Oncology · 2018 · 991 citations · Full text

Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial

Reinhard Dummer, Paolo A. Ascierto, Helen Gogas et al. · The Lancet Oncology · 2018 · 578 citations

, , +7

Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells

Laure A Moutouh-de Parseval, Dominique Verhelle, Emilia Glezer et al. · Journal of Clinical Investigation · 2008 · 178 citations · Full text

, , +15

Pomalidomide augments fetal hemoglobin production without the myelosuppressive effects of hydroxyurea in transgenic sickle cell mice

Steffen E. Meiler, Marlene Wade, F. Kutlar et al. · Blood · 2011 · 84 citations · Full text

1–4 of 4